Altria Group heads into Wednesday's Q2 earnings report with a subtly shifted setup from just two days ago — options hedging has unwound slightly while short sellers have quietly added to positions.
The most notable change since the earnings preview published Sunday is in options. The put/call ratio has dropped back to 0.92 from 1.22 on Monday — still above its 20-day average of 0.85, but well off the defensive peak. That pullback coincides with a 2.6% single-day gain in the stock to $74.82, and a 2.5% rise on the week. Investors who were paying heavily for downside protection appear to have trimmed those hedges as the stock moved higher. The PCR z-score of 0.36 now sits close to neutral — a meaningful retreat from the near-two-standard-deviation reading flagged earlier in the week.
Short interest, however, has moved in the opposite direction. Bears added modestly, with SI rising 4.3% over the week to 3.1% of the free float — reversing some of the 7.4% monthly decline noted previously. The build is not dramatic; 52.6 million shares short at 3.1% of float is not an aggressive position. The borrow market remains completely unthreatening: availability has actually tightened slightly to around 2,370% of short interest from roughly 3,000% earlier in the week, but that is still an extraordinary pool of supply. Cost to borrow is running at 0.43%, up about 20% on the week yet trivially low in absolute terms. This is not a short book with conviction — it reads more like tactical positioning into an event than a structural bear thesis.
The Street backdrop is modestly constructive but divided. UBS raised its target to $79 on July 7, the most recent bellwether move, maintaining a Buy. Barclays holds an Underweight with a $64 target — a full $11 below the current price, which creates an immediate data-consistency tension: the stock has already traded well through that target. The consensus sits at Hold with eight analysts at that rating and no Sells flagged in the current data. The forward P/E of 12.9 has barely moved over the past month, suggesting the recent price strength reflects multiple expansion rather than estimate upgrades. The dividend score ranks in the 99th percentile — the yield remains a core part of the bull case, even if recent price gains have compressed it slightly. Bulls point to Marlboro's 42% domestic market share and On! oral tobacco growing to 8.8% retail share. Bears flag declining cigarette consumption, with fewer than 15% of adults 18 and over reporting recent usage, and legacy smokeless products dragging on overall sales momentum.
The two most recent prior earnings prints are worth noting. The Q1 April 30 report produced a 9.3% single-day gain and a muted 1.2% five-day follow-through — a classic buy-the-catalyst, fade-the-momentum pattern. The May print delivered a smaller 2.2% day-one move and a 3.0% five-day drift. The stock enters this report up nearly 30% year-to-date and pressing against levels where UBS's $79 target becomes relevant within a single good session.
What to watch tomorrow: whether the On! oral tobacco volume numbers justify the year-to-date re-rating, and whether management commentary on cigarette volume declines and pricing power is strong enough to hold the stock at current levels against a consensus still anchored to Hold.
See the live data behind this article on ORTEX.
Open MO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
